<DOC>
	<DOCNO>NCT00911248</DOCNO>
	<brief_summary>Formation new blood vessel ( angiogenesis ) important tumor growth neurofibromatosis type 2 ( NF2 ) . It known tumor make protein call vascular endothelial growth factor ( VEGF ) high level VEGF tumor blood many patient NF2 . VEGF stimulate formation blood vessel supply tumor nutrient oxygen . PTC299 oral drug show decrease production VEGF animal model human cancer . In animal model , oral PTC299 administration decrease VEGF level tumor bloodstream , decrease blood vessel number tumor , significantly slow halt tumor growth . Safety study research animal indicate good tolerability dos drug level higher plan clinical study . Results Phase 1a study healthy volunteer indicate PTC299 achieves level PTC299 bloodstream know active animal model human tumor . This Phase 2 study design test hypothesis PTC299 tolerable show evidence VEGF reduction , antitumor activity , hear improvement administer orally patient NF2 .</brief_summary>
	<brief_title>PTC299 Treatment Neurofibromatosis Type 2</brief_title>
	<detailed_description>The study conduct 2 stage . In Stage 1 study , 11 patient receive daily treatment PTC299 administer 100 mg/dose twice per day 1 year tumor progression . If subject respond tumor shrinkage improvement hearing , study stop . If ≥1 11 subject respond , study proceed Stage 2 enroll additional 14 subject total 25 subject .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 2</mesh_term>
	<mesh_term>6- ( 4-fluorophenyl ) -2,3-dihydro-5- ( 4-pyridinyl ) imidazo ( 2,1-b ) thiazole</mesh_term>
	<criteria>Age ≥18 year Diagnosis NF2 Presence vestibular schwannomas Evidence progressive increase vestibular schwannoma size worsen hearing loss due vestibular schwannoma Adequate functional status ( Karnofsky Performance Score ≥60 ) Adequate bone marrow , liver , kidney function If sexually active , willingness use effective barrier medical contraception For woman childbearing potential , pregnancy breastfeed Discontinuation therapy ( except corticosteroid ) treatment NF2 resolution acute toxic effect prior therapy Willingness ability comply schedule visit , drug administration plan , laboratory test , study procedure , study restriction Willingness provide inform consent Uncontrolled hypertension , major bleeding , HIV infection , recent acute cardiovascular event Prior exposure another antiangiogenic therapy ( eg , bevacizumab , sunitinib )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Angiogenesis</keyword>
	<keyword>Neurofibromatosis</keyword>
	<keyword>Post-transcriptional control</keyword>
	<keyword>PTC299</keyword>
	<keyword>VEGF</keyword>
</DOC>